814P Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3

M. R. Migden; C. Schmults; N. Khushanlani; A. Guminski; A. L. Chang; K. Lewis; G. Ansstas; S. E. Bowyer; B. G. M. Hughes; D. Schadendorf; B. Modi; L. Dunn; L. Flatz; A. Hauschild; S-Y. Yoo; J. Booth; F. Seebach; I. Lowy; M. G. Fury; D. Rischin

doi:10.1016/j.annonc.2022.07.940

814P Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3

M. R. Migden, C. Schmults, N. Khushanlani, A. Guminski, A. L. Chang, K. Lewis, G. Ansstas, S. E. Bowyer, B. G. M. Hughes, D. Schadendorf, B. Modi, L. Dunn, L. Flatz, A. Hauschild, S-Y. Yoo, J. Booth, F. Seebach, I. Lowy, M. G. Fury, D. Rischin

UWA Centre for Medical Research (affiliated with the Harry Perkins Institute of Medical Research)

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

20 Citations (Web of Science)

Original language	English
Pages (from-to)	S918-S919
Number of pages	2
Journal	Annals of Oncology
Volume	33
Issue number	7
DOIs	https://doi.org/10.1016/j.annonc.2022.07.940
Publication status	Published - Sept 2022
Event	2022 Annual Meeting of the European-Society-for-Medical-Oncology - , France Duration: 9 Sept 2022 → 13 Sept 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.annonc.2022.07.940

Cite this

Migden, M. R., Schmults, C., Khushanlani, N., Guminski, A., Chang, A. L., Lewis, K., Ansstas, G., Bowyer, S. E., Hughes, B. G. M., Schadendorf, D., Modi, B., Dunn, L., Flatz, L., Hauschild, A., Yoo, S.-Y., Booth, J., Seebach, F., Lowy, I., Fury, M. G., & Rischin, D. (2022). 814P Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3. Annals of Oncology, 33(7), S918-S919. https://doi.org/10.1016/j.annonc.2022.07.940

@article{4872bc4892684cdcba91aa12b74e12ff,

title = "814P Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3",

author = "Migden, \{M. R.\} and C. Schmults and N. Khushanlani and A. Guminski and Chang, \{A. L.\} and K. Lewis and G. Ansstas and Bowyer, \{S. E.\} and Hughes, \{B. G. M.\} and D. Schadendorf and B. Modi and L. Dunn and L. Flatz and A. Hauschild and S-Y. Yoo and J. Booth and F. Seebach and I. Lowy and Fury, \{M. G.\} and D. Rischin",

year = "2022",

month = sep,

doi = "10.1016/j.annonc.2022.07.940",

language = "English",

volume = "33",

pages = "S918--S919",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "7",

note = "2022 Annual Meeting of the European-Society-for-Medical-Oncology, ESMO 2022 ; Conference date: 09-09-2022 Through 13-09-2022",

}

Migden, MR, Schmults, C, Khushanlani, N, Guminski, A, Chang, AL, Lewis, K, Ansstas, G, Bowyer, SE, Hughes, BGM, Schadendorf, D, Modi, B, Dunn, L, Flatz, L, Hauschild, A, Yoo, S-Y, Booth, J, Seebach, F, Lowy, I, Fury, MG & Rischin, D 2022, '814P Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3', Annals of Oncology, vol. 33, no. 7, pp. S918-S919. https://doi.org/10.1016/j.annonc.2022.07.940

TY - JOUR

T1 - 814P Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC)

T2 - 2022 Annual Meeting of the European-Society-for-Medical-Oncology

AU - Migden, M. R.

AU - Schmults, C.

AU - Khushanlani, N.

AU - Guminski, A.

AU - Chang, A. L.

AU - Lewis, K.

AU - Ansstas, G.

AU - Bowyer, S. E.

AU - Hughes, B. G. M.

AU - Schadendorf, D.

AU - Modi, B.

AU - Dunn, L.

AU - Flatz, L.

AU - Hauschild, A.

AU - Yoo, S-Y.

AU - Booth, J.

AU - Seebach, F.

AU - Lowy, I.

AU - Fury, M. G.

AU - Rischin, D.

PY - 2022/9

Y1 - 2022/9

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:000866211601085

U2 - 10.1016/j.annonc.2022.07.940

DO - 10.1016/j.annonc.2022.07.940

M3 - Abstract/Meeting Abstract

SN - 0923-7534

VL - 33

SP - S918-S919

JO - Annals of Oncology

JF - Annals of Oncology

IS - 7

Y2 - 9 September 2022 through 13 September 2022

ER -

814P Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3

UN SDGs

Access to Document

Other files and links

Cite this